NR AXMT
AU Galeno,R.; Ingrosso,L.; Valanzano,A.; Sbriccoli,M.; Ladogana,A.; Liu,Q.; Graziano,S.; Di Bari,M.A.; Agrimi,U.; Cardone,F.
TI First and Second Passage of Human Transmissible Spongiform Encephalopathies to Mice
QU International Conference - Prion 2007 (26.-28.9.2007) Edinburgh International Conference Centre, Edinburgh, Scotland, UK - Book of Abstracts: Epidemiology, Risk Assessment and Transmission P04.93
IA http://www.prion2007.com/pdf/Prion Book of Abstracts.pdf
PT Konferenz-Poster
AB
We report on the first and second passage of a panel of sporadic and genetic Creutzfeldt-Jakob disease (CJD) cases. Sporadic CJD (sCJD) of different types (MM1, MV1, VV1/2, MM2, MV2, VV2), genetic CJD (gCJD) associated with V210I or E200K PrP mutations, and Gerstmann-Sträussler syndrome (GSS) associated with P102L mutation were intracerebrally and intraperitoneally inoculated into C3H mice. Third passage is underway for most of the sCJD and all gCJD cases. Results from primary and secondary passage are shown in the table. As clinical signs were not reliable, presence of PrPres was used to gauge transmissibility. Brains from PrPres positive animals were inoculated for the second passage, when PrPres positive animals were not found, a pool of PrPres negative brains was used. Sporadic CJD MM1, MV1 and MM2 were positive at the first passage while VV1/2, MV2 and VV2 were not. The second passage was also positive for MM1 and MM2. While sCJD MV1 did not transmit at the second passage into C3H mice it did however transmit to bank voles (Nonno R. et al. 2006). The second passage of MV2 and VV2 sCJD is still in course.
V210I gCJD was transmitted both at the first and the second passage while P102L GSS was not. On the other hand, E200K gCJD was negative at the first passage and positive at the secondary.
In conclusion, serial transmission of sCJD and gCJD cases to C3H mice did not result in a strain adaptation since at the second passage neither the incubation period shortened nor the number of PrPres positive animals increased. Furthermore, positive transmission (MV1 sCJD) at the primary passage did not warrant a successful transmission in the second one. Finally, the absence of PrPres positive animals at the first passage does not necessarily imply a negative outcome at the second one (E200K gCJD).
FIRST PASSAGE SECOND PASSAGE
INOCULUM Days to sacrifice PrP27-30 Days to sacrifice PrP27-30 positive/analysed (n alive, dpi) positive/analysed
sCJD MM1 685, 719 2/5 704, 787, 815 3/9 sCJD MV1 649, 695 2/5 >350 0/13 sCJD MM2 596, 679, 743, 743 4/8 330 (19, >370 dpi) 1/1 sCJD VV1/2 >600 0/5 >400 0/8 sCJD MV2 >365 0/7 302 (19, >370 dpi) Not tested sCJD VV2 >500 0/8 (20, >370 dpi) gCJD V210I 762, 771, 774 3/6 704 1/7 gCJD E200K >500 0/4 669 1/6 GSS P102L >500 0/3 >700 0/7
AD R. Galeno, L. Ingrosso, A. Valanzano, M. Sbriccoli, A. Ladogana, Q. Liu, S. Graziano, F. Cardone, Istituto Superiore di Sanità, Dept. of Cell Biology and Neurosciences, Italy; M.A. Di Bari, U. Agrimi, Istituto Superiore di Sanità, Dept. of Food Safety and Veterinary Public Health, Italy
SP englisch
PO Schottland